Alimentary pharmacology & therapeutics
-
Aliment. Pharmacol. Ther. · Oct 2020
Multicenter StudyComorbidity, not patient age, is associated with impaired safety outcomes in vedolizumab- and ustekinumab-treated patients with inflammatory bowel disease-a prospective multicentre cohort study.
Few data are available on the effects of age and comorbidity on treatment outcomes of vedolizumab and ustekinumab in inflammatory bowel disease (IBD). ⋯ Comorbidity - but not age - is associated with an increased risk of hospitalisations on either treatment, and with any infection on vedolizumab. This underlines the importance of comorbidity assessment and safety monitoring of IBD patients.
-
Aliment. Pharmacol. Ther. · Aug 2020
ReviewClinical assessment for high-risk patients with non-alcoholic fatty liver disease in primary care and diabetology practices.
Primary care practitioners (PCPs) and diabetologists are at the frontline of potentially encountering patients with NASH. Identification of those at high risk for adverse outcomes is important. ⋯ Due to the growing burden of NAFLD and NASH, PCPs and diabetologists are faced with increased patient encounters in their clinical practices necessitating referral decisions. To assist in identifying high-risk NASH patients requiring specialty care, we provide a simple and easy to use algorithm.
-
Aliment. Pharmacol. Ther. · Aug 2020
Comparative Study Observational StudyComparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease.
Direct comparisons are lacking between vedolizumab and tumour necrosis factor (TNF)-antagonist therapy in Crohn's disease (CD). ⋯ There was a lower risk of non-infectious serious adverse events, but not serious infections, with vedolizumab vs TNF-antagonist therapy, with no significant difference for achieving disease remission.